Esomeprazole — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for GERD (Gastroesophageal Reflux Disease)

• Famotidine
• Lansoprazole
• Omeprazole
• Pantoprazole
• Ranitidine

Also listed for Peptic Ulcer Disease

• Sucralfate

Other medications in Gastrointestinal

• Hyoscyamine
• Loperamide
• Mesalamine
• Azathioprine
• Dapsone
• Dicyclomine

Dosage forms and strengths for Esomeprazole (FDA label)

Esomeprazole Magnesium Delayed-Release Capsules • 20 mg esomeprazole in opaque, hard gelatin, amethyst colored capsules with two radial bars in yellow on the cap and esomeprazole magnesium 20 mg in yellow on the body. • 40 mg esomeprazole in opaque, hard gelatin, amethyst colored capsules with three radial bars in yellow on the cap and esomeprazole magnesium 40 mg in yellow on the body. • Esomeprazole Magnesium Delayed-Release Capsules: 20 mg and 40 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: d68c9247-91c7-4e0f-adc4-2cfa7446580f. Label effective date: November 30, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Esomeprazole (FDA label)

The following serious adverse reactions are described below and elsewhere in labeling: • Acute Tubulointerstitial Nephritis [see Warnings and Precautions ( 5.2 )] • Clostridium difficile-Associated Diarrhea [see Warnings and Precautions ( 5.3 )] • Bone Fracture [see Warnings and Precautions ( 5.4 )] • Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.5 )] • Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions ( 5.6 )] • Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions ( 5.8 )] • Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.9 )] • Fundic Gland Polyps [see Warnings and Precautions ( 5.13 )] Most common adverse reactions ( 6.1 ): • Adults (≥18 years) (>1%) are: headache, diarrhea, nausea, flatulence, abdominal pain, constipation, and dry mouth.

Source: FDA prescribing information (DailyMed). Set ID: d68c9247-91c7-4e0f-adc4-2cfa7446580f. Label effective date: November 30, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Esomeprazole (FDA label)

• Esomeprazole magnesium is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6.2 )]. • For information about contraindications of amoxicillin and clarithromycin, indicated in combination with esomeprazole magnesium for H. pylori eradication to reduce the risk of duodenal ulcer recurrence, refer to the Contraindications section of the respective prescribing information. • Proton pump inhibitors (PPIs), including esomeprazole magnesium are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions ( 7 )]. • Known hypersensitivity to substituted benzimidazoles or any component of the formulation. (4) • Patients receiving rilpivirine-containing products. (4, 7) • Refer to the Contraindications section of the prescribing information for amoxicillin and clarithromycin, when administered in combination with esomeprazole magnesium delayed-release capsules. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: d68c9247-91c7-4e0f-adc4-2cfa7446580f. Label effective date: November 30, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Esomeprazole (FDA label)

• Gastric Malignancy : In adults, symptomatic response does not preclude the presence of gastric malignancy.

Source: FDA prescribing information (DailyMed). Set ID: d68c9247-91c7-4e0f-adc4-2cfa7446580f. Label effective date: November 30, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Esomeprazole (FDA label)

Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with esomeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Esomeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.

Source: FDA prescribing information (DailyMed). Set ID: d68c9247-91c7-4e0f-adc4-2cfa7446580f. Label effective date: November 30, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.